|
|
|
| Clinical study of Tongmai Yangxin Pills in the treatment of female primary stable microvascular angina#br# |
| RUN Jingmo ZHANG Shuaiyong SU Yongjian LI Jie YAN Liqiu▲ YUAN Bomin▲ |
| Department of Cardiology, Cangzhou Central Hospital, Hebei Medical University, Hebei Province, Cangzhou 061001, China |
|
|
|
Abstract Objective To evaluate the clinical effect of Tongmai Yangxin Pills on female primary stable microvascular angina (MVA). Methods A total of 577 female patients who were first diagnosed with primary stable MVA in Cangzhou Central Hospital of Hebei Medical University from June 2015 to June 2020 were selected. They were divided into control group (288 cases) and Tongmai Yangxin Pills group (289 cases) by random number table method. The control group was given conventional drug treatment for coronary heart disease, and Tongmai Yangxin Pills group was given Tongmai Yangxin Pills on the basis of control group. All patients were followed up for six months, the significant effective rate and effective rate, rehospitalization rate, and incidence of adverse reaction between two groups were compared, grading of angina by Canadian Society of Cardiology (CCS) and positive rate of electrocardiogram exercise test before and after treatment between two groups were compared. Results The clinical effect in Tongmai Yangxin Pills group was better than that in control group (P ＜ 0.05). After treatment, the grading of angina by CCS in the two groups was lower than that before treatment, and which in Tongmai Yangxin Pills group was lower than that in the control group (P ＜ 0.05). After treatment, the positive rate of electrocardiogram exercise test in both groups was lower than that before treatment, and which in Tongmai Yangxin Pills group was lower than that in control group (P ＜ 0.05). The rehospitalization rate of Tongmai Yangxin Pills group was lower than that in control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Tongmai Yangxin Pills has a significant clinical effect on female patients with primary stable MVA.
|
|
|
|
|
|
[1] 中华医学会心血管病学分会基础研究学组，中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会女性心脏健康学组，等.冠状动脉微血管疾病诊断和治疗的中国专家共识[J].中国循环杂志，2017，32（5）：421-430.
[2] Olson MB，Kelsey SF，Matthews K，et al. Symptoms，myocardial ischaemia and quality of life in women：results from the NHLBI-sponsored WISE Study [J]. Eur Heart J，2003，24（16）：1506-1514.
[3] Johnson BD，Shaw LJ，Buchthal SD，et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease：results from the National Institutes of Health-National Heart，Lung，and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation（WISE） [J]. Circulation，2004，109（24）：2993-2999.
[4] Jespersen L，Hvelplund A，Abildstrom SZ，et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events [J]. Eur Heart J，2012，33（6）：734-744.
[5] Gulati M，Cooper-DeHoff RM，McClure C，et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease：a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project [J]. Arch Intern Med，2009， 169（9）：843-850.
[6] Anderson RD，Petersen JW，Mehta PK，et al. Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort：The NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction（WISE-CVD）[J]. J Interv Cardiol，2019，2019：7169275.
[7] Michelsen MM，Mygind ND，FrestadD，et al. Women with Stable Angina Pectoris and No Obstructive Coronary Artery Disease：Closer to a Diagnosis [J]. Eur Cardiol，2017， 12（1）：14-19.
[8] Tjoe B，Barsky L，Wei J，et al. Coronary microvascular dysfunction：Considerations for diagnosis and treatment [J]. Cleve Clin J Med，2021，88（10）：561-571.
[9] Sedlak TL，Lee M，Izadnegahdar M，et al. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease [J]. Am Heart J，2013， 166（1）：38-44.
[10] Tao S，Huang Y，Chen Z，et al. Rapid identification of anti-inflammatory compounds from Tongmai Yangxin Pills by liquid chromatography with high-resolution mass spectrometry and chemometric analysis [J]. J Sep Sci，2015，38（11）：1881-1893.
[11] 庞建中，杨继，陈善夫，等.通脉养心丸治疗稳定型心绞痛气阴两虚证的临床研究[J].辽宁中医杂志，2021，48（10）：115-119.
[12] Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later [J]. Can J Cardiol，2002，18（4）：371-379.
[13] 及跃，于晓雪，王效增，等.尼可地尔治疗冠状动脉微血管病变性心绞痛的临床疗效分析[J].中国实用医药，2020， 15（2）：112-115.
[14] 韩孝宇，安建立，王文广，等.尼可地尔联合曲美他嗪对改善老年急性心肌梗死急性PCI术后心功能的作用[J].内科急危重症杂志，2018，24（6）：467-471.
[15] Kaski JC，Crea F，Gersh BJ，et al. Reappraisal of Ischemic Heart Disease [J]. Circulation，2018，138（14）：1463-1480.
[16] Jansen TPJ，Konst RE，Elias-Smale SE，et al. Assessing Microvascular Dysfunction in Angina With Unobstructed Coronary Arteries：JACC Review Topic of the Week [J]. J Am Coll Cardiol，2021，78（14）：1471-1479.
[17] Del Buono MG，Montone RA，Camilli M，et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases：JACC State-of-the-Art Review [J]. J Am Coll Cardiol，2021，78（13）：1352-1371.
[18] Ya’qoub L，Elgendy IY，Pepine CJ. Syndrome of Nonobstructive Coronary Artery Diseases：A Comprehensive Overview of Open Artery Ischemia [J]. Am J Med，2021，S0002-9343（21）：474-475.
[19] Shaw LJ，Shaw RE，Merz CN，et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry [J]. Circulation，2008，117（14）：1787-1801.
[20] Kenkre TS，Malhotra P，Johnson BD，et al. Ten-Year Mortality in the WISE Study（Women’s Ischemia Syndrome Evaluation）[J]. Circ Cardiovasc Qual Outcomes，2017，10（12）：e003863.
[21] Sedlak T，Herscovici R，Cook-Wiens G，et al. Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease： A Report From WISE （Women's Ischemia Syndrome Evaluation）[J]. J Am Heart Assoc，2020，9（7）：e013234.
[22] Aldiwani H，Zaya M，Suppogu N，et al. Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease：A Report from the WISE（Women’s Ischemia Syndrome Evaluation）Study [J]. J Am Heart Assoc，2020，9（4）：e013168.
[23] 徐一兰，高杉，邓兵，等.通脉养心丸干预冠心病稳定性心绞痛气阴两虚证的临床生化基础研究[J].天津中医药，2019，36（1）：18-22.
[24] Cui Y，Li C，Zeng C，et al. Tongmai Yangxin pills anti-oxidative stress alleviates cisplatin-induced cardiotoxicity： Network pharmacology analysis and experimental evidence [J]. Biomed Pharmacother，2018，108：1081-1089.
[25] 尹倚艰，徐贵成，刘坤，等.通脉养心丸治疗期前收缩随机双盲安慰剂平行对照多中心临床研究[J].中西医结合心脑血管病杂志，2016，14（10）：1123-1126.
[26] 庞稳泰，张俊华，翟静波，等.通脉养心丸治疗冠心病心绞痛随机对照试验的系统评价[J].中国中药杂志，2019，44（11）：2390-2396.
|
|
|
|
